- Report
- May 2024
- 137 Pages
Global
From €6214EUR$6,499USD£5,201GBP
- Report
- June 2024
- 200 Pages
Global
From €7601EUR$7,950USD£6,363GBP
- Report
- January 2022
- 60 Pages
Global
From €3777EUR$3,950USD£3,161GBP
- Report
- January 2022
- 60 Pages
Global
From €3777EUR$3,950USD£3,161GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1912EUR$2,000USD£1,601GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1195EUR$1,250USD£1,000GBP
- Report
- May 2022
- 40 Pages
Global
From €1912EUR$2,000USD£1,601GBP
Status epilepticus (SE) is a medical emergency characterized by a prolonged seizure or series of seizures without full recovery of consciousness in between. It is a life-threatening condition that requires immediate medical attention. SE is a major cause of morbidity and mortality in the Central Nervous System (CNS) drug market.
The SE drug market is composed of a variety of drugs used to treat the condition, including benzodiazepines, barbiturates, and anticonvulsants. These drugs are used to control seizures, reduce the risk of recurrence, and prevent further neurological damage. The SE drug market is highly competitive, with a number of companies offering a range of products.
Some of the major players in the SE drug market include Pfizer, GlaxoSmithKline, Sanofi, Novartis, and Johnson & Johnson. These companies offer a range of products, including benzodiazepines, barbiturates, and anticonvulsants, to treat SE. Show Less Read more